Torrent Pharma last week reported a 2.8 per cent rise in its consolidated net profit to Rs 330 crores for the quarter ended in June.
The company had posted a net profit of Rs 321 crores for the corresponding period of the previous fiscal, Torrent Pharma said in a regulatory filing.
Consolidated revenue from operations of the company stood at Rs 2,134 crores for the quarter under consideration. It was Rs 2,056 crores for the same period a year ago, it added.
India revenues at Rs 1,093 crores, grew by 18 per cent for the quarter ended 30th June, 2021, Torrent Pharma said.
Regarding COVID drugs, the company has launched Baricitinib during the quarter, and is currently conducting clinical trials for Molnupiravir; more partnerships are under evaluation to widen the COVID portfolio, it added.
The US revenues at Rs 266 crores, were down by 29 per cent. Sales were lower due to price erosion in the base business and lack of new approvals pending re-inspection of facilities, Torrent Pharma said.
Edits by EP News Bureau